Lu-177 PSMA therapy treats men with metastatic castration-resistant prostate cancer (mCRPC), a type that has spread to other parts of the body and stopped responding to hormone therapy. The therapy works by sending radiation directly to cancer cells. A radioactive molecule binds to PSMA, a protein that prostate cancer cells make in large amounts. The cell pulls the molecule inside, and the radiation damages the cancer cell DNA. This method may still work after standard chemotherapy stops working.
This article explains how the therapy works, why chemotherapy eventually stops working in mCRPC, and what the evidence shows for men who have already received prior treatments.
What Is PSMA and Why Does Prostate Cancer Make So Much of It?
PSMA stands for prostate-specific membrane antigen. It is a protein on the outer surface of prostate cells. Normal prostate tissue produces small amounts. Prostate cancer cells, especially advanced cancer, produce much more.
Research on Lu-177 PSMA therapy shows that cancer cells make much more PSMA than normal tissue. This amount tends to increase as the disease advances. In mCRPC, levels are often at their highest. This makes PSMA a reliable target: more PSMA means more places for a PSMA-targeting molecule to attach.
PSMA is an internalizing receptor. When a molecule binds to PSMA on the surface of a cancer cell, the cell pulls that molecule through its membrane and inside. Whatever attaches to the PSMA-binding ligand, including radioactive material, gets delivered directly into the cancer cell. This step is what makes the method precise.
How the Therapy Works in Three Steps
Lutetium Lu 177 vipivotide tetraxetan (brand name Pluvicto) works through three steps. These steps explain why it can reach cancer in places that systemic chemotherapy often cannot, and why cancer resistant to chemotherapy may still respond to this therapy.
Step one: binding. After a short IV infusion, a small targeting molecule called a ligand enters the bloodstream. It attaches to PSMA on the surface of cancer cells. Wherever cancer expressing PSMA is found, in bone, lymph nodes, or soft tissue, the ligand binds to it.
Step two: internalization. Once the ligand binds to PSMA, the cancer cell pulls it inside. The lutetium-177 radioisotope comes in with the ligand. The radiation is now inside the cancer cell, not circulating freely in surrounding tissue.
Step three: DNA damage. Lutetium-177 gives off beta radiation. Beta particles travel only a very short distance in tissue, less than 2 millimeters at most. This focused radiation breaks DNA strands inside the cancer cell and may reach a few neighboring tumor cells. Enough DNA damage stops the cell from copying itself and can kill the cell.
The Prostate Cancer Foundation explains it this way: the radiation goes directly to the cancer, not all over the body.
Why Does Standard Chemotherapy Eventually Stop Working in mCRPC?
Taxane chemotherapy drugs (like docetaxel and cabazitaxel) work by breaking down the internal structures that cells use to divide. Cancer cells divide faster than most healthy cells, so they are more damaged.
But taxane chemotherapy treats the whole body, not just tumors. This is why it causes side effects like fatigue, lower blood counts, and peripheral neuropathy (tingling or numbness in the hands and feet).
Over time, cancer cells adapt. They may change the proteins that taxanes attack or find new ways to divide. Once this happens, higher doses cause more harm than good. Men who have already received taxane treatment often have weakened bone marrow, which limits what treatments are safe next.
Lu-177 PSMA therapy does not target cell division. It targets the PSMA protein on the cancer cell surface. This is a different approach, which is why cancer cells that resist taxanes may still respond to Lu-177, as long as they still make enough PSMA.
What Does the Clinical Evidence Show?
The main evidence comes from the VISION trial, a large phase 3 study. It included men whose cancer had progressed after hormone therapy and one or two rounds of taxane chemotherapy, with PSMA-positive disease confirmed by PSMA-PET scan.
According to the VISION trial in the New England Journal of Medicine, men receiving lutetium Lu 177 vipivotide tetraxetan and standard care had a median survival of 15.3 months, compared to 11.3 months with standard care alone. The death rate was meaningfully lower in the treatment group. Time before cancer grew on imaging was 8.7 months in the treatment group and 3.4 months in the control group.
These results do not apply to every patient. Response rates vary based on PSMA levels, prior treatment, and other factors. The article Lu-177 PSMA Therapy Does Not Work for Everyone explains who is most likely to benefit.
Based on VISION results, the FDA approved Pluvicto in March 2022 for men with PSMA-positive mCRPC who had already received hormone therapy and taxane chemotherapy. The FDA expanded approval in early 2025 to men who have received hormone therapy when it is clinically appropriate to delay taxane chemotherapy.
How Does a PSMA-PET Scan Determine Eligibility?
Before starting Lu-177 PSMA therapy, your oncology team must confirm that your cancer is making PSMA at a sufficient level. This is done with a PSMA-PET scan, usually using a radiotracer called gallium-68 gozetotide (Ga-68 PSMA-11).
The scan uses the same targeting method as the therapy. The radiotracer binds to PSMA on cancer cells and sends out a signal that a PET scanner can detect. The result is a whole-body map showing where your cancer is making PSMA and how much.
For Lu-177 to work, PSMA levels need to be high enough across all cancer areas. If large areas of cancer show low or no PSMA, those areas would not get enough radiation, and the therapy may not help. A nuclear medicine specialist looks at the whole picture, not just whether any PSMA is present.
If you have had a PSMA-PET scan and want to understand what it means for your eligibility, the article What Your PSMA-PET Results Mean for Lu-177 Eligibility explains how results are read and what they mean for your treatment options.
If you are considering treatment internationally, you can request a Lu-177 eligibility review through Art of Healing Cancer. If Lu-177 is not right for your case, the team can discuss other options for your stage and history.
Who May Not Qualify for Lu-177 PSMA Therapy?
Lu-177 PSMA therapy is not right for everyone with advanced prostate cancer. It matters to know this because it affects your treatment plan. The main reasons someone may not qualify include:
- PSMA-low or PSMA-negative disease. If the scan shows low or no PSMA across tumor sites, the therapy cannot reach enough cancer to work.
- Serious kidney problems. The kidneys clear lutetium-177, so serious kidney dysfunction may make treatment unsafe.
- Low blood cell counts. Prior treatments, especially chemotherapy, can weaken bone marrow. Very low platelet or red blood cell counts may make further treatment unsafe.
- Liver cancer with low PSMA. A large amount of liver cancer that does not make PSMA is generally not a good fit for this therapy.
If your eligibility is unclear, a specialist in nuclear medicine can review your scans and recent blood work and give you a more precise answer.
What Does the Treatment Course Involve?
Lu-177 PSMA therapy is an IV infusion that usually takes 20 to 30 minutes. The standard treatment is one infusion every six weeks, for up to six cycles.
The six-week gap is intentional. Between cycles, your care team checks blood counts and kidney function. The gap also gives healthy bone marrow time to recover before the next dose.
Because the treatment uses radioactive material, you need to follow radiation safety steps for about a week after each infusion, mainly limiting close contact with young children and pregnant women. The article What to Expect in Your First Lu-177 PSMA Cycle explains the details of the infusion day, monitoring, and at-home safety steps.
Supporting Bone Health During Treatment
Most men receiving Lu-177 PSMA therapy continue hormone therapy (ADT) at the same time, as it remains part of standard mCRPC treatment. Long-term hormone therapy can weaken bones, a concern for men with bone cancer. Your oncologist may recommend bone-protective medication. Some men also use supplements for bone and joint support. Before starting any supplement, including options like Ayurnomics's Joint and Bone range, check with your oncologist, as some may interact with cancer treatment.
When to Talk to Your Doctor
Talk to your oncologist about Lu-177 PSMA therapy if any of these apply:
- Your prostate cancer continues to grow after hormone therapy and taxane chemotherapy.
- You have not yet had a PSMA-PET scan and want to know if your cancer may qualify.
- You have PSMA-positive imaging but have not had a formal eligibility review for Lu-177.
- You are researching treatment options in countries where this therapy is more accessible or cheaper than where you live.
You can submit your PSMA-PET scan results and recent lab work through the Lutetium Therapy contact form for a review. If Lu-177 is not right for you, the team can discuss other options.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Can Lu-177 PSMA therapy work if chemotherapy has already stopped helping?
It may, provided your cancer still expresses PSMA at an adequate level. The VISION trial specifically enrolled men who had already received taxane-based chemotherapy, and results showed improved survival compared to standard care alone. PSMA expression needs to be confirmed first with a PSMA-PET scan before eligibility can be assessed for your individual case.
How is PSMA targeting different from the way taxane chemotherapy works?
Taxane chemotherapy disrupts cell division broadly - it affects any rapidly dividing cell in the body, including healthy ones, which is why it causes side effects across multiple tissues. Lu-177 PSMA therapy uses a molecule that binds specifically to the PSMA protein expressed in high amounts on prostate cancer cells. The radiation is carried inside the cancer cell directly, rather than being dispersed throughout the body. Cancer cells resistant to taxanes may still respond to Lu-177 if they continue to express PSMA.
Can I have Lu-177 PSMA therapy if I have not yet had chemotherapy?
This depends on the approvals in your country and your specific clinical situation. In the US, the FDA expanded its approval in early 2025 to include men who have received androgen-receptor-pathway inhibitor therapy and for whom delaying taxane-based chemotherapy is considered clinically appropriate. Your oncologist can advise whether your treatment history qualifies under current guidelines in your location.
How many cycles of Lu-177 PSMA therapy does a standard course involve?
The standard course is up to six cycles, given once every six weeks. Your oncology team monitors your response and tolerability between cycles. Not all patients complete six cycles - some may stop earlier if the disease is no longer responding or if side effects become difficult to manage. The decision to continue or pause is based on ongoing monitoring throughout the course.
Is a PSMA-PET scan always required before starting Lu-177 PSMA therapy?
Yes. Confirming PSMA expression through a PSMA-PET scan is a standard prerequisite before eligibility can be determined. The scan maps PSMA levels across all tumor sites in the body. If significant areas of cancer show low or absent PSMA expression, the therapy is unlikely to be effective at those sites and will generally not be offered.
